{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:27:18Z","timestamp":1792902438775,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Henan Program for Science and Technology Development","award":["232102311042"],"award-info":[{"award-number":["232102311042"]}]},{"name":"Talent Support Program of Xinxiang Medical University","award":["XYBSKYZZ201924"],"award-info":[{"award-number":["XYBSKYZZ201924"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13780-2","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T04:50:26Z","timestamp":1740459026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["CAR-NK cells with dual targeting of PD-L1 and MICA\/B in lung cancer tumor models"],"prefix":"10.1186","volume":"25","author":[{"given":"Lingtong","family":"Zhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongye","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"1","key":"13780_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"13780_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"issue":"2","key":"13780_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/08830185.2015.1018419","volume":"34","author":"JA Figueroa","year":"2015","unstructured":"Figueroa JA, Reidy A, Mirandola L, et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol. 2015;34(2):154\u201387. https:\/\/doi.org\/10.3109\/08830185.2015.1018419","journal-title":"Int Rev Immunol"},{"issue":"4","key":"13780_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"issue":"1","key":"13780_CR5","doi-asserted-by":"publisher","first-page":"e000450","DOI":"10.1016\/j.canlet.2019.11.033","volume":"8","author":"KP Fabian","year":"2020","unstructured":"Fabian KP, Padget MR, Donahue RN, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020;8(1):e000450. https:\/\/doi.org\/10.1016\/j.canlet.2019.11.033","journal-title":"J Immunother Cancer"},{"issue":"1","key":"13780_CR6","doi-asserted-by":"publisher","first-page":"e000450","DOI":"10.1136\/jitc-2019-000450","volume":"8","author":"KP Fabian","year":"2020","unstructured":"Fabian KP, Padget MR, Donahue RN, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020;8(1):e000450. https:\/\/doi.org\/10.1136\/jitc-2019-000450","journal-title":"J Immunother Cancer"},{"issue":"2","key":"13780_CR7","doi-asserted-by":"publisher","first-page":"e000873","DOI":"10.1136\/jitc-2020-000873","volume":"8","author":"JE Park","year":"2020","unstructured":"Park JE, Kim SE, Keam B, et al. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. J Immunother Cancer. 2020;8(2):e000873. https:\/\/doi.org\/10.1136\/jitc-2020-000873","journal-title":"J Immunother Cancer"},{"issue":"6428","key":"13780_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446\u20138. https:\/\/doi.org\/10.1038\/363446a0","journal-title":"Nature"},{"issue":"16","key":"13780_CR9","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1073\/pnas.1817147116","volume":"116","author":"YJ Xie","year":"2019","unstructured":"Xie YJ, Dougan M, Jailkhani N, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci U S A. 2019;116(16):7624\u201331. https:\/\/doi.org\/10.1073\/pnas.1817147116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"13780_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41392-021-00462-1","volume":"6","author":"F Mo","year":"2021","unstructured":"Mo F, Duan S, Jiang X, et al. Nanobody-based chimeric antigen receptor T cells designed by CRISPR\/Cas9 technology for solid tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):80. https:\/\/doi.org\/10.1038\/s41392-021-00462-1","journal-title":"Signal Transduct Target Ther"},{"key":"13780_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fimmu.2015.00097","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang J, Basher F, Wu JD. NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol. 2015;6:97. https:\/\/doi.org\/10.3389\/fimmu.2015.00097","journal-title":"Front Immunol"},{"issue":"8","key":"13780_CR12","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419\u201331. https:\/\/doi.org\/10.1038\/s41591-021-01436-0","journal-title":"Nat Med"},{"issue":"12","key":"13780_CR13","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41(12):2238\u201347. https:\/\/doi.org\/10.1200\/JCO.22.01725","journal-title":"J Clin Oncol"},{"issue":"7","key":"13780_CR14","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2(7):e105. https:\/\/doi.org\/10.1038\/mtna.2013.32","journal-title":"Mol Ther Nucleic Acids"},{"key":"13780_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.molimm.2019.07.009","volume":"114","author":"C Guo","year":"2019","unstructured":"Guo C, Wang X, Zhang H, et al. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells. Mol Immunol. 2019;114:108\u201313. https:\/\/doi.org\/10.1016\/j.molimm.2019.07.009","journal-title":"Mol Immunol"},{"key":"13780_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molimm.2023.12.001","volume":"165","author":"C Guo","year":"2024","unstructured":"Guo C, Guo X, Li X, et al. The SpyCatcher-SpyTag interaction mediates tunable anti-tumor cytotoxicity of NK cells. Mol Immunol. 2024;165:11\u20138. https:\/\/doi.org\/10.1016\/j.molimm.2023.12.001","journal-title":"Mol Immunol"},{"key":"13780_CR17","doi-asserted-by":"publisher","first-page":"115136","DOI":"10.1016\/j.biopha.2023.115136","volume":"165","author":"L Zhi","year":"2023","unstructured":"Zhi L, Wang X, Gao Q, et al. Intrinsic and extrinsic factors determining natural killer cell fate: phenotype and function. Biomed Pharmacother. 2023;165:115136. https:\/\/doi.org\/10.1016\/j.biopha.2023.115136","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"13780_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/2326-6066.CIR-17-0207","volume":"6","author":"VYS Oei","year":"2018","unstructured":"Oei VYS, Siernicka M, Graczyk-Jarzynka A, et al. Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors. Cancer Immunol Res. 2018;6(4):467\u201380. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0207","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"13780_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/cmi.2014.91","volume":"12","author":"C Sun","year":"2015","unstructured":"Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12(3):292\u2013302. https:\/\/doi.org\/10.1038\/cmi.2014.91","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"13780_CR20","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3390\/ijms19113648","volume":"19","author":"PS Sung","year":"2018","unstructured":"Sung PS, Jang JW. Natural killer cell dysfunction in hepatocellular carcinoma: pathogenesis and clinical implications. Int J Mol Sci. 2018;19(11):3648. https:\/\/doi.org\/10.3390\/ijms19113648","journal-title":"Int J Mol Sci"},{"issue":"6","key":"13780_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(6):498\u2013508. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0231","journal-title":"Cancer Immunol Res"},{"key":"13780_CR22","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975","journal-title":"EBioMedicine"},{"issue":"2","key":"13780_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/cells9020321","volume":"9","author":"J Hambach","year":"2020","unstructured":"Hambach J, Riecken K, Cichutek S, et al. Targeting CD38-expressing multiple myeloma and Burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs). Cells. 2020;9(2):321. https:\/\/doi.org\/10.3390\/cells9020321","journal-title":"Cells"},{"issue":"1","key":"13780_CR24","first-page":"64","volume":"9","author":"F You","year":"2019","unstructured":"You F, Wang Y, Jiang L, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9(1):64\u201378.","journal-title":"Am J Cancer Res"},{"key":"13780_CR25","doi-asserted-by":"publisher","unstructured":"Watzl C, Long EO. Signal transduction during activation and inhibition of natural killer cells. Curr Protoc Immunol. 2010;Chap 11:10.1002\/0471142735.im1109bs90. https:\/\/doi.org\/10.1002\/0471142735.im1109bs90","DOI":"10.1002\/0471142735.im1109bs90"},{"issue":"6","key":"13780_CR26","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","volume":"73","author":"YH Chang","year":"2013","unstructured":"Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73(6):1777\u201386. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3558","journal-title":"Cancer Res"},{"issue":"74","key":"13780_CR27","doi-asserted-by":"publisher","first-page":"eabl3995","DOI":"10.1126\/sciimmunol.abl3995","volume":"7","author":"Q Xiao","year":"2022","unstructured":"Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. Size-dependent activation of CAR-T cells. Sci Immunol. 2022;7(74):eabl3995. https:\/\/doi.org\/10.1126\/sciimmunol.abl3995","journal-title":"Sci Immunol"},{"issue":"6","key":"13780_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/gt.2012.88","volume":"20","author":"C Papayannakos","year":"2013","unstructured":"Papayannakos C, Daniel R. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. Gene Ther. 2013;20(6):581\u20138. https:\/\/doi.org\/10.1038\/gt.2012.88","journal-title":"Gene Ther"},{"key":"13780_CR29","doi-asserted-by":"publisher","unstructured":"Bari R, Granzin M, Tsang KS et al. A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy [published correction appears in Front Immunol. 2019;10:2784.]. Front Immunol. 2019;10:2001. https:\/\/doi.org\/10.3389\/fimmu.2019.02001","DOI":"10.3389\/fimmu.2019.02001"},{"issue":"1","key":"13780_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41420-022-00906-9","volume":"8","author":"F Yao","year":"2022","unstructured":"Yao F, Jin Z, Zheng Z, et al. HDAC11 promotes both NLRP3\/caspase-1\/GSDMD and caspase-3\/GSDME pathways causing pyroptosis via ERG in vascular endothelial cells. Cell Death Discov. 2022;8(1):112. https:\/\/doi.org\/10.1038\/s41420-022-00906-9. Published 2022 Mar 12.","journal-title":"Cell Death Discov"},{"key":"13780_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.molimm.2023.07.013","volume":"161","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Cai X, Wang B, Zhang B, Xu Y. Exploring the molecular mechanisms of the involvement of GZMB-Caspase-3-GSDME pathway in the progression of rheumatoid arthritis. Mol Immunol. 2023;161:82\u201390. https:\/\/doi.org\/10.1016\/j.molimm.2023.07.013","journal-title":"Mol Immunol"},{"issue":"2","key":"13780_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/jcp.22043","volume":"223","author":"CC Lu","year":"2010","unstructured":"Lu CC, Chen JK. Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. J Cell Physiol. 2010;223(2):343\u201351. https:\/\/doi.org\/10.1002\/jcp.22043","journal-title":"J Cell Physiol"},{"issue":"2","key":"13780_CR33","first-page":"166","volume":"67","author":"HH van Ravenswaay Claasen","year":"1992","unstructured":"van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD16\u2009+\u2009macrophages in antitumor cytotoxicity. Lab Invest. 1992;67(2):166\u201374.","journal-title":"Lab Invest"}],"updated-by":[{"DOI":"10.1186\/s12885-025-13821-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13780-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:52:58Z","timestamp":1740981178000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13780-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13780"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13780-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5406191\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-025-13821-w","URL":"https:\/\/doi.org\/10.1186\/s12885-025-13821-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study protocol was approved by the Animal Ethics Committee of Xinxiang Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"337"}}